Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer

Colorectal Carcinoma Clinical Trial

Official title:

The Efficacy and Safety of Toripalimab Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Patients With Advanced MSI-H or dMMR Colorectal Cancer: an Open-label, Multicenter, Single-arm, Phase Ib/II Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04988191
• Other study ID #: JS001-ISS-115
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 24, 2020
• Est. completion date: December 24, 2023

Study information

• Verified date: July 2021
• Source: Peking University
• Contact: Lin Shen, Professor
• Phone: 86-10-88196561
• Email: linshenpku[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a trial investigating the efficacy and safety of Toripalimab combined with bevacizumab and chemotherapy as neoadjuvant therapy in patients with advanced microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR) colorectal cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 44
• Est. completion date: December 24, 2023
• Est. primary completion date: June 24, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Histologically confirmed colorectal adenocarcinoma meeting any of the following criterion: a) T3-4 resectable rectal cancer; b) T1-2 rectal cancer located within 12 cm from the anal verge and refusing direct surgery or radiation therapy; c) T4a-b resectable colon cancer.

2. Microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR).

3. Measurable disease according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria and haven't received any local treatment.

4. Eastern Cooperative Oncology Group (ECOG) 0-1.

5. Fully aware of this study and having signed informed consent.

6. Age 18 to 75 years old without gender limitation.

7. Good compliance.

8. Absolute neutrophil count =1500/mm3, platelet =100,000/mm3, Hb =10g/dl, serum creatinine =1.5 times ULN, creatinine clearance rate =50mL/min, ALT and AST =2.5 times ULN, INR or aPTT =1.5 times ULN (INR =2 times ULN and aPTT in normal range for patients who are on prophylactic anticoagulant therapy within 14 days before study treatment), total bilirubin level =2 times ULN (within 7 days before study treatment).

9. Women of childbearing age should confirm that serum pregnancy test is negative and agree to use effective contraceptive methods during study treatment and the following 60 days.

Exclusion Criteria:

1. Previously received anti-PD1 or anti-PDL1 or anti-PDL2 or anti-CTLA4.

2. Uncontrolled active bleeding from the primary tumor or intestinal obstruction.

3. Contraindications of bevacizumab or irinotecan.

4. Hypersensitivity to other monoclonal antibodies.

5. Any active, known or suspected autoimmune disease.

6. Uncontrolled pleural effusion, pericardial effusion, or ascites to a moderate or greater extent.

7. History of one of the following dieases: idiopathic pulmonary fibrosis, organized pneumonia (eg. bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia and interstitial pneumonia, or evidence of active pneumonia through enhanced chest CT screening.

8. Major surgery within 4 weeks before enrollment and haven't fully recovered from the previous surgery.

9. Active bleeding or abnormal coagulation (aPTT >43s or INR >1.5 times ULN), or having a tendency to bleed or receiving thrombolytic or anticoagulant therapy.

10. Previously received allogeneic stem cell or parenchymal organ transplantation.

11. Any significant clinical or laboratory abnormality that the investigator considers to influence the safety assessment, eg. uncontrolled active infection, uncontrolled diabetes, hypertension that cannot be reduced to normal range with monotherapy, grade II or above peripheral neuropathy, congestive heart failure, heart disease (class II or higher) as defined by the New York College of Cardiology, myocardial infarction within 3 months prior to enrollment, unstable arrhythmias, unstable angina pectinis, chronic kidney disease, abnormal thyroid function and previous or co-existing malignancies.

12. History of uncorrected serum electrolyte disturbances such as potassium, calcium and magnesium.

13. HIV infection.

14. Active hepatitis B or hepatitis C.

15. Pregnancy or lactation period, or unwilling to use contraception during the trial.

16. With other malignancy within 5 year, except cervical carcinoma in situ, basal or squamous skin cancer, local prostatic carcinoma and ductal carcinoma in situ.

17. Use corticosteroids (dose of prednisone or similar drugs> 10mg/day) or other immunosuppressive agents within 14 days before enrollment.

18. Patients with active tuberculosis (TB) who are receiving anti-TB treatment or have received anti-TB treatment within 1 year.

19. Active infection, or treatment with oral or intravenous antibiotics within the first 2 weeks prior to neoadjuvant therapy, except prophylactic administration.

20. Anti-infective vaccine (eg. influenza vaccine, varicella vaccine, etc.) injection within 4 weeks before neoadjuvant therapy.

21. Previous participation in other clinical trials within 4 weeks before neoadjuvant therapy.

22. Any other disease, metabolic disorder, abnormal physical examination or abnormal laboratory results that may contrainn the use of trial drug, or affect the reliability of study results, or lead to high risk of treatment complications, or affect patient compliance.

Related Conditions & MeSH terms

• Colorectal Carcinoma
• Colorectal Neoplasms

Intervention

Drug:
• Toripalimab
Neoadjuvant therapy: Toripalimab is given by intravenous infusion at 3mg/kg d1 every 2 weeks for 3 cycles. Adjuvant therapy: Toripalimab is given by intravenous infusion at a dose of 240mg every 3 weeks for up to 9 cycles.
• Bevacizumab
Neoadjuvant therapy: Bevacizumab is given by intravenous infusion at 5mg/kg d1 every 2 weeks for 3 cycles.
• Irinotecan
Neoadjuvant therapy: Irinotecan is given by intravenous infusion at 180mg/m2 d1 every 2 weeks for 2 cycles.

Locations

Country	Name	City	State
China	Peking University Cancer Hospital and Institute	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological complete response rate based on blinded, independent, central review	Percentage of patients who achieve pathological complete response (pCR) based on blinded, independent, central review (BICR).	10 weeks
Secondary	R0 recession rate	Percentage of patients who achieve R0 recession.	10 weeks
Secondary	Time to surgery	Measure of time from study treatment to surgery.	10 weeks
Secondary	Pathological complete response rate assessed by local investigator	Percentage of patients who achieve pathological complete response (pCR) based on assessment of local investigator.	10 weeks
Secondary	Pathological complete response rate based on blinded, independent, central review (BICR) and the assessment of local investigator	Percentage of patients who achieve pathological complete response (pCR) based on both blinded, independent, central review (BICR) and assessment of local investigator.	10 weeks
Secondary	Tumor regression grade (TRG)		10 weeks
Secondary	Objective response rate	Percentage of patients who achieve partial response (PR) or complete response (CR) based on Response Evaluation Criteria In Solid Tumors (RECIST).	Up to 3 years
Secondary	Event free survival	Measure of time from study treatment to disease progression or death.	Up to 3 years
Secondary	Disease-free survival	Measure of time from the date of surgery to disease relapse or death.	Up to 3 years
Secondary	One-year or two-year disease-free survival rate	Percentage of patients who achieve disease-free survival lasting for more than one and two years respectively from the date of surgery.	Up to 2 years
Secondary	One-year or two-year overall survival rate	Percentage of patients who achieve survival for more than one and two years respectively from date of first dose.	Up to 2 years
Secondary	Score of life quality	Accessment of life quality based on EORTC QLQ-C30 and EORTC QLQ-CR29 scale.	Until 30 days after the last treatment
Secondary	Incidence of Treatment-Related Adverse Events	Number of adverse events.	Until 30 days after the last treatment